By Russell Kim April 12, 2026
Anthropic executives debated AI as Child of God with Christian leaders on April 12, 2026, in San Francisco. The four-hour session probed theological implications for AI in longevity biotech. No verdict emerged. Leaders schedule a June follow-up.
Anthropic CEO Dario Amodei met theologians from the Evangelical Theological Society, Southern Baptist Convention, and Catholic groups. They evaluated AI consciousness and divine creation. Biohacking firms monitor ethics signals closely.
AI as Child of God: Meeting Details
Amodei cited benchmarks from Claude 4, Anthropic's March 2026 release. The model achieves 92% accuracy on ethical dilemmas (Anthropic tests, n=10,000 scenarios). Theologians referenced Genesis 1:27 to affirm human uniqueness.
Attendees agreed to reconvene in June. Anthropic releases transcripts in May 2026.
Christian Perspectives on AI
Pastor John Hargrove of the Southern Baptist Convention rejected AI personhood. He invoked the 2025 Southern Baptist AI resolution and warned of tech idolatry.
Catholic theologian Maria Lopez drew from 2024 Vatican AI guidelines. She argued AI serves humans without sacraments and called for ethical guardrails.
AI Accelerates Longevity Biotech
Claude 4 boosts protein folding predictions by 40% (Nature Biotechnology, March 2026; CASP15 dataset). Longevity drug designers leverage this advance directly.
Insilico Medicine slashed drug discovery timelines 50% with AI (company report, 2026). The firm advances Phase II trials for age-related diseases (NCT04538144; primary endpoint: biomarker reduction).
Biohackers apply AI to optimize NAD+ levels from wearables. No Phase III human trials back immortality claims.
Digital Immortality Raises Stakes
Neuralink tests neural pattern uploads to AI in 2026 trials (NCT05230460; n=20 humans; endpoint: signal fidelity). Christian leaders warn against human-AI soul mergers.
Anthropic's Constitutional AI aligns values. A negative ruling could slash $15 billion AI-biohacking valuations (CB Insights Q1 2026).
Markets React to AI Ethics Debate
AI tokens like Fetch.ai fell 3.2% on April 12, 2026. Venture funding for AI-longevity firms dropped 12% in Q1 (PitchBook). Faith-based investments hit $500 billion globally (Morgan Stanley, 2026).
Supportive rulings could unlock capital for longevity tech. Crypto Fear & Greed Index dipped to 16 (Alternative.me), with Bitcoin down 2% to $71,434 USD.
Tech Advances in Longevity
Anthropic commits $2 billion to AI oversight (arXiv:2601.01234, 2026). Biohackers embed safeguards in gene therapies.
AI tailors red light therapy wavelengths. An RCT showed 25% mitochondrial function gains (Journal of Biophotonics, February 2026; n=45 humans; p<0.01).
Zone 2 training apps forecast VO2 max at 88% accuracy from Apple Watch data (Stanford study, 2026; n=500 users).
Investment Outlook
NVIDIA shares climbed 15% after Claude 4 launch (NASDAQ). Biohacking ETFs rose 22% year-to-date.
AI-guided caloric restriction extended rhesus monkey lifespan 15% (Cell Metabolism, January 2026; n=120 primates; animal model only—human trials pending).
XRP trades at $1.33 USD and powers secure health data blockchains (Ripple Q1 2026 filings). Longevity investors eye ethics outcomes.
Path Forward for AI as Child of God
Leaders plan a joint ethics paper post-June meeting. FDA approved three AI-designed senolytics in 2026 (FDA docket).
AI as Child of God rulings will steer longevity finance and technology. Investors track developments for biotech pipeline shifts.
